Perianal abscesses in infants are not associated with Crohn’s disease in a surgical cohort.

Perianal abscesses in infants are not associated with Crohn’s disease in a surgical cohort. J Crohns Colitis. 2019 May 22;: Authors: Roskam M, de Meij T, Bakx R, Gemke R Abstract BACKGROUND AND AIMS: The aim of this study is to search for an association between infantile perianal abscesses and (development of) Crohn’s disease in a surgical population of children. METHODS: Patients who were surgically treated in the Amsterdam UMC between January 2000 and December 2014 were included in this retrospective cohort study. Data collected: sex, date of birth, underlying…

Read More

Long-term Outcomes of Paediatric Patients Admitted with Acute Severe Colitis – A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN.

Long-term Outcomes of Paediatric Patients Admitted with Acute Severe Colitis – A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2019 May 23;: Authors: Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S, Huynh H, Wine E, Shah N, Sladek M, de Meij TG, Romano C, Dipasquale V, Lionetti P, Afzal NA, Aloi M, Lee K, Martín-de-Carpi J,…

Read More

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis. 2019 May 22;: Authors: Smeets FGM, Liedorp PR, van der Poel M, Miclea RL, Masclee AAM, Pierik M Abstract Use of ustekinumab in Crohn’s disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn’s disease, who developed an anaplastic large cell T cell…

Read More

Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2019 May 03;: Authors: Ma C, Panaccione NR, Nguyen TM, Guizzetti L, Parker CE, Hussein IM, Vande Casteele N, Khanna R, Dulai PS, Singh S, Feagan BG, Jairath V Abstract BACKGROUND AND AIMS: Nocebo effects, adverse outcomes occurring in patients receiving inert therapy, contribute to adverse event (AE) reporting in randomized controlled trials (RCTs). High placebo AE rates may result in inaccurate estimation of treatment-related AEs. We estimate the…

Read More

Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease.

Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease. J Crohns Colitis. 2019 Apr 25;: Authors: Sifuentes-Dominguez L, Starokadomskyy P, Welch J, Gurram B, Park JY, Koduru P, Burstein E Abstract The genetic basis of inflammatory bowel disease remains to be elucidated completely. Here we report on a patient with inflammatory bowel disease who has mosaic tetrasomy of the short arm of chromosome 9, a genomic region that harbours the type I interferon gene cluster. We show that increased interferon activation is present in peripheral blood and intestinal tissue from this…

Read More

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis. J Crohns Colitis. 2019 May 15;: Authors: Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG Abstract BACKGROUND: Adalimumab is administered via a pre-filled syringe or spring-loaded pen. In a previous study in Crohn’s disease, higher drug levels were observed in syringe users. The aim of this study was to evaluate the…

Read More

Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.

Related Articles Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Feb 13;: Authors: Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC Abstract BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn’s disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission. METHODS: We performed…

Read More

Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort.

Related Articles Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort. J Crohns Colitis. 2019 May 10;: Authors: Lo B, Vind I, Vester-Andersen MK, Bendtsen F, Burisch J Abstract BACKGROUND: Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative Colitis (UC), places a high burden on health care resources. To date, no study has assessed the combined direct and indirect cost of IBD in a population-based setting. Our aim was to assess this in a population-based inception cohort with…

Read More

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.

Related Articles Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019 May 10;: Authors: Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L Abstract BACKGROUND AND AAIMS: We aimed to summarize the existing data on the effectiveness of vedolizumab in extra-intestinal manifestations (EIMs) in inflammatory bowel disease (IBD). METHODS: We conducted a systematic literature search in PubMed and Cochrane Library, through October 2018. Interventional and non-interventional studies, as well as case-series studying vedolizumab and EIMs in adult patients with…

Read More
<< Go Back